×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MYGN – myriad genetics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MYGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/19
09:15 am
mygn
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
Low
Report
FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test
2/16
04:41 pm
mygn
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 [Yahoo! Finance]
Low
Report
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 [Yahoo! Finance]
2/16
04:15 pm
mygn
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
Low
Report
Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026
1/27
08:50 am
mygn
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
Low
Report
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
1/22
04:00 am
mygn
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm [Yahoo! Finance]
Medium
Report
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm [Yahoo! Finance]
1/21
06:20 am
mygn
Myriad Genetics (NASDAQ:MYGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Myriad Genetics (NASDAQ:MYGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/12
09:11 am
mygn
Myriad Genetics Q4 and 2025 revenue ranges include consensus [Seeking Alpha]
Medium
Report
Myriad Genetics Q4 and 2025 revenue ranges include consensus [Seeking Alpha]
1/12
08:30 am
mygn
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Low
Report
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/11
05:21 pm
mygn
Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: INTEGRATED CORE STRATEGIES (US) LLC
Medium
Report
Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: INTEGRATED CORE STRATEGIES (US) LLC
2/9
07:55 am
mygn
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP
Medium
Report
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP
2/3
05:30 pm
mygn
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Haas Kevin Richard
Low
Report
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Haas Kevin Richard
2/3
05:30 pm
mygn
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Wheeler Benjamin Richard
Low
Report
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Wheeler Benjamin Richard
2/3
05:30 pm
mygn
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Muzzey Dale
Low
Report
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Muzzey Dale
2/3
05:30 pm
mygn
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Verratti Mark
Low
Report
Form 4 MYRIAD GENETICS INC For: Feb 02 Filed by: Verratti Mark
1/13
04:40 pm
mygn
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC
Low
Report
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC
1/12
08:31 am
mygn
Form 8-K MYRIAD GENETICS INC For: Jan 12
Low
Report
Form 8-K MYRIAD GENETICS INC For: Jan 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/1
Form 8-K MYRIAD GENETICS INC For: Aug 01
55.0%
4/6 Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC 25.2%
3/23 Myriad Announces Board of Directors Leadership Transition 12.5%
11/6 GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions 11.5%
8/16 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.6%
12/4 Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening 7.9%
3/25 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 7.1%
8/2 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "neutral" rating. 6.8%
11/23 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm 6.4%
4/28 Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 6.2%
4/6 Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC 25.2%
3/23 Myriad Announces Board of Directors Leadership Transition 12.5%
11/6 GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions 11.5%
8/16 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.6%
12/4 Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening 7.9%
3/25 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 7.1%
8/2 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "neutral" rating. 6.8%
11/23 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm 6.4%
4/28 Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 6.2%
TOP News Decliners
8/13
Q4/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.400 ActVsEst 0.010 - Beat
-42.8%
11/4 Q1/2020 9/30/2019 EPS 0.080 ZacksConsensus 0.260 ActVsEst (0.180) - Miss -40.1%
2/6 Q2/2020 12/31/2019 EPS 0.230 ZacksConsensus 0.220 ActVsEst 0.010 - Beat -28.2%
5/7 Form 8-K MYRIAD GENETICS INC For: May 07 -21.4%
8/14 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. -9.9%
8/22 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention -8.1%
6/14 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "underweight" rating on the stock. -7.7%
2/7 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from to . -6.3%
3/17 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.0%
8/7 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer -4.6%
11/4 Q1/2020 9/30/2019 EPS 0.080 ZacksConsensus 0.260 ActVsEst (0.180) - Miss -40.1%
2/6 Q2/2020 12/31/2019 EPS 0.230 ZacksConsensus 0.220 ActVsEst 0.010 - Beat -28.2%
5/7 Form 8-K MYRIAD GENETICS INC For: May 07 -21.4%
8/14 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. -9.9%
8/22 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention -8.1%
6/14 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "underweight" rating on the stock. -7.7%
2/7 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from to . -6.3%
3/17 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.0%
8/7 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: